menu
    • menu

    Company profile for Dogwood Therapeutics

    NEW Drugs in Dev: 5
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Dogwood Therapeutics is a biotechnology company focused on developing novel treatments for pain and fatigue-related illnesses. Their lead candidate, Halneuron®, is a sodium channel blocker targeting chemotherapy-induced neuropathic pain (CINP) and other severe pain conditions. Additionally, they are pioneering antiviral combination therapies to treat diseases like Long COVID and fibromyalgia, which are linked to abnormal immu...
    Dogwood Therapeutics is a biotechnology company focused on developing novel treatments for pain and fatigue-related illnesses. Their lead candidate, Halneuron®, is a sodium channel blocker targeting chemotherapy-induced neuropathic pain (CINP) and other severe pain conditions. Additionally, they are pioneering antiviral combination therapies to treat diseases like Long COVID and fibromyalgia, which are linked to abnormal immune responses triggered by viruses. Dogwood emphasizes non-opioid pain management solutions with minimal side effects, aiming to address significant unmet medical needs.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Dogwood TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    44 Milton Avenue Alpharetta, GA 30009
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://dwtx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/dogwoodther/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    Village de la Chimie

    Not Confirmed

    envelop Contact Supplier

    Village de la Chimie

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Dogwood Therapeutics Ongoing Halneuron Trial at 50%; Top Results
    Dogwood Therapeutics Ongoing Halneuron Trial at 50%; Top Results

    02 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/02/3230281/0/en/Dogwood-Therapeutics-Announces-50-Enrollment-in-Ongoing-Halneuron-Phase-2b-Trial-Top-Line-Results-Anticipated-in-Q3-2026.html

    GLOBENEWSWIRE
    02 Feb 2026
    Share Share
    Dogwood Therapeutics Secures $26.8M For Halneuron Phase 2B
    Dogwood Therapeutics Secures $26.8M For Halneuron Phase 2B

    12 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/12/3216902/0/en/Dogwood-Therapeutics-Inc-Announces-Financing-of-up-to-26-8-Million-to-Progress-Halneuron-Through-Phase-2b-Development.html

    GLOBENEWSWIRE
    12 Jan 2026
    Share Share
    Dogwood Enrolls First 100 Patients In Halneuron(R) Ph 2B Trial
    Dogwood Enrolls First 100 Patients In Halneuron(R) Ph 2B Trial

    11 Nov 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-11-11/dogwood-announces-enrollment-of-first-100-patients-in-ongoing-halneuron-r-phase-2b-trial-interim-s

    PHARMIWEB
    11 Nov 2025
    Share Share
    Dogwood Therapeutics Reports Third Quarter 2025 Financial Results
    Dogwood Therapeutics Reports Third Quarter 2025 Financial Results

    06 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/06/3182625/0/en/Dogwood-Therapeutics-Reports-Third-Quarter-2025-Financial-Results.html

    GLOBENEWSWIRE
    06 Nov 2025
    Share Share
    Dogwood Therapeutics To Release Q3 2025 Financial Results
    Dogwood Therapeutics To Release Q3 2025 Financial Results

    30 Oct 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-10-30/dogwood-therapeutics-to-report-third-quarter-2025-financial-results-on-thursday-november-6-2025

    PHARMIWEB
    30 Oct 2025
    Share Share
    Dogwood Therapeutics To Attend Maxim Growth Summit 2025
    Dogwood Therapeutics To Attend Maxim Growth Summit 2025

    14 Oct 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-10-14/dogwood-therapeutics-to-participate-at-the-maxim-growth-summit-2025

    PHARMIWEB
    14 Oct 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search